Hu Y W, Birch P, Balaskas E, Zeibdawi A, Scalia V, Thériault-Valin S A, Gill P, Aye M T
National Testing Laboratory, Canadian Red Cross Society, Ottawa, Ontario, Canada.
J Clin Microbiol. 1996 Jun;34(6):1412-9. doi: 10.1128/jcm.34.6.1412-1419.1996.
A new serological assay, the recombinant flow cytometric immunofluorescence assay (r-FIFA), was developed for the early detection of human immunodeficiency virus type 1 (HIV-1) antibodies by using recombinant insoluble forms of HIV-1 Gag-p45, Gag-gp41 chimeric protein, gp160, Po197 polyprotein as antigens and autologous carriers through flow cytometry. These recombinant proteins were expressed in insect cells by a baculovirus expression system. Eight anti-HIV-1 seroconversion panels, a low-titer anti-HIV-1 panel from Boston Biomedica Inc. (BBI), and three HIV-1 seroconversion specimens from the Provincial Health Laboratory of Ontario, Toronto, Ontario, Canada (PHL), were tested and analyzed by r-FIFA. In sensitivity comparisons between r-FIFA and tests licensed by the U.S. Food and Drug Administration, which were used to test all of the HIV-1 panels from BBI, detection of HIV-1 antibody by r-FIFA was on average greater than 20 days earlier than that by enzyme immunoassay. The sensitivity of r-FIFA has permitted the detection of HIV-1-specific immunoglobulin G (IgG), IgM, and IgA antibodies during seroconversion. A kinetic analysis of HIV-1 antibody production of r-FIFA has shown that either IgG or IgM, or both, can be detected, depending on the phase and type of the immune response in the HIV-1-infected individual. Both primary and secondary immune responses were observed during this period. The r-FIFA results suggest that implementation of r-FIFA may significantly reduce the "window" period from the time of infection to the time of seroconversion, with earlier detection of antibodies after initial infection. This would also make it possible for us to understand the immune response and the precise mechanisms of immunopathogenesis in the early period of HIV-1 infection.
一种新的血清学检测方法,即重组流式细胞免疫荧光检测法(r-FIFA),通过使用重组不溶性形式的HIV-1 Gag-p45、Gag-gp41嵌合蛋白、gp160、Po197多蛋白作为抗原,并通过流式细胞术使用自体载体,用于早期检测1型人类免疫缺陷病毒(HIV-1)抗体。这些重组蛋白通过杆状病毒表达系统在昆虫细胞中表达。使用r-FIFA对8个抗HIV-1血清转化样本组、来自波士顿生物医学公司(BBI)的低滴度抗HIV-1样本组以及来自加拿大安大略省多伦多市安大略省卫生实验室(PHL)的3个HIV-1血清转化标本进行了检测和分析。在r-FIFA与美国食品药品监督管理局批准的用于检测BBI所有HIV-1样本组的检测方法之间的敏感性比较中,r-FIFA检测HIV-1抗体的时间平均比酶免疫测定法早20多天。r-FIFA的敏感性使得在血清转化期间能够检测到HIV-1特异性免疫球蛋白G(IgG)、IgM和IgA抗体。对r-FIFA检测HIV-1抗体产生的动力学分析表明,根据HIV-1感染个体免疫反应的阶段和类型,可以检测到IgG或IgM,或两者都能检测到。在此期间观察到了初次和二次免疫反应。r-FIFA的结果表明,实施r-FIFA可能会显著缩短从感染到血清转化的“窗口期”,在初次感染后更早地检测到抗体。这也将使我们有可能了解HIV-1感染早期的免疫反应和免疫发病机制的确切机制。